Previous studies have shown that dimerization of EGFR and HER2 leads to the rapid activation of downstream kinases, such as Akt, PCK−α, and ERK1/2−MAPK, leading to the loss of ER−α expression in breast cancer cells [55,56]. This evidence concerns the gene ERBB2 and breast carcinoma.